Viking Therapeutics Inc. recently released a corporate presentation highlighting its ongoing efforts in developing novel therapeutics for metabolic and endocrine diseases. The presentation outlines multiple clinical programs, including VK2735, a GLP-1/GIP dual agonist for obesity, which successfully achieved its primary endpoint in the Phase 2 VENTURE study, with a Phase 3 trial planned for the second quarter of 2025. The oral version of VK2735 is currently in Phase 2, following positive proof-of-concept results in Phase 1. Additionally, an amylin agonist for obesity is in the pipeline, with an investigational new drug application planned for the fourth quarter of 2025. Other programs include VK2809, a selective thyroid receptor-β agonist for MASH, and VK0214, a selective thyroid receptor-β agonist for X-ALD, both of which have shown promising results in recent trials. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.